Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cerus Corp (NQ: CERS )

6.000 USD +0.080 (+1.35%)
Streaming Delayed Price Updated: 10:02 AM EDT, Apr 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Cerus Corp

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
From PR Newswire
Health Canada Approves INTERCEPT Blood System for Plasma
Health Canada Approves INTERCEPT Blood System for Plasma 
From Business Wire News Releases
Cerus Corporation Reports First Quarter 2016 Results
Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2016. 
From Business Wire News Releases
Cerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System
Cerus Announces that the Walter Reed National Military Medical Center Has Entered into Routine Use of the INTERCEPT Blood System 
From Business Wire News Releases
Cerus to Present at the Deutsche Bank 41st Annual Health Care Conference on May 5, 2016
Cerus to Present at the Deutsche Bank 41st Annual Health Care Conference on May 5, 2016 
From Business Wire News Releases
Cerus to Release First Quarter 2016 Results on May 3, 2016
Cerus to Release First Quarter 2016 Results on May 3, 2016 
From Business Wire News Releases
Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma
Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma 
From Business Wire News Releases
Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets
Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets 
From Business Wire News Releases
Covered Call Alerts For Kinder Morgan, Himax Technologies Inc, US Steel, Yahoo! and CERUS Corporation Released By InvestorsObserver
InvestorsObserver issues critical PriceWatch Alerts for KMI, HIMX, X, YHOO and CERS. 
From PR Newswire
Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology
Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology 
From Business Wire News Releases
Cerus Corporation Reports Fourth Quarter and Year End 2015 Results
Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and year ended December 31, 2015. 
From Business Wire News Releases
Cerus Enters Into Agreement With Banco de Sangre de Servicios Mutuos for the Use of INTERCEPT Platelets and Plasma in Puerto Rico to Sustain Blood Supply During Zika Epidemic
Cerus Enters into Agreement with Banco de Sangre de Servicios Mutuos for the Use of INTERCEPT Platelets and Plasma in Puerto Rico to Sustain Blood Supply During Zika Epidemic 
From Business Wire News Releases
Cerus to Present at the Cowen and Company 36th Annual Health Care Conference on March 9, 2016
Cerus to Present at the Cowen and Company 36th Annual Health Care Conference on March 9, 2016. 
From Business Wire News Releases
Covered Call Alerts For Seadrill, Valeant Pharmaceuticals, CERUS Corporation, Amazon.com and Microsoft Released By InvestorsObserver
From PR Newswire
Cerus to Release Fourth Quarter and Year End 2015 Results on March 8, 2016
Cerus to Release Fourth Quarter and Year End 2015 Results on March 8, 2016 
From Business Wire News Releases
FDA’s Zika Guidance Document Allows Use of Pathogen Reduction to Reduce Transfusion Risk and Maintain Local Blood Availability
FDA’s Zika Guidance Document Allows Use of Pathogen Reduction to Reduce Transfusion Risk and Maintain Local Blood Availability 
From Business Wire News Releases
Biotechnology Equities Update -- Cerus, Seattle Genetics, Sangamo Biosciences, and ImmunoGen
Tags Publishing & Media
From ACCESSWIRE
Covered Call Alerts For Bank of America, CERUS Corporation, Seadrill, Johnson & Johnson and Facebook Released By InvestorsObserver
InvestorsObserver issues critical PriceWatch Alerts for BAC, CERS, SDRL, JNJ and FB. 
From PR Newswire
Various Development Advancements for Targeted Treatment Therapies for Rare Diseases & Disorders Lead to Newest Orphan Drug Designations by the U.S. FDA
From PR Newswire
Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma
Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma 
From Business Wire News Releases
AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease
AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease 
From Business Wire News Releases
Cerus Appoints New Leadership for Europe, Middle East and Africa Region
Cerus Appoints New Leadership for Europe, Middle East and Africa Region 
From Business Wire News Releases
Cerus and LifeShare Blood Centers Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
Cerus and LifeShare Blood Centers Enter into Agreement for the Use of INTERCEPT Platelets and Plasma 
From Business Wire News Releases
Cerus Announces Agreement with Blood Systems, Inc. for the Use of INTERCEPT Platelets and Plasma
Cerus Announces Agreement with Blood Systems, Inc. for the Use of INTERCEPT Platelets and Plasma 
From Business Wire News Releases
Pharma Industry Poised for Fast Start in 2016 as U.S. Food & Drug Administration Receives Requests for Newest Orphan Drug Designations & Rare Disease Treatments
From PR Newswire
Cerus Announces Rhode Island Blood Center Enters into Agreement for the Use of INTERCEPT Platelets and Plasma
Cerus Announces Rhode Island Blood Center Enters into Agreement for the Use of INTERCEPT Platelets and Plasma 
From Business Wire News Releases
Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma
Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Plateets and Plasma 
From Business Wire News Releases
Cerus Announces Agência Nacional de Vigilância Sanitária Approval of the INTERCEPT Blood System for Platelets and Plasma in Brazil
Cerus Announces Agência Nacional de Vigilância Sanitária Approval of the INTERCEPT Blood System for Platelets and Plasma in Brazil 
From Business Wire News Releases
First Patient Enrolled in Cerus’ Phase IV PIPER Study
First Patient Enrolled in Cerus’ Phase IV PIPER Study 
From Business Wire News Releases
Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.